Last Update 21 Mar 26

Fair value Increased 0.71%

XRAY: Dental Market Stabilisation And Q4 Model Resets Will Shape 2026 Outlook

Analysts have nudged the DENTSPLY SIRONA price target higher to $14.54 from $14.43, reflecting updated models that factor in revised revenue growth assumptions, a slightly lower profit margin outlook, a modestly higher future P/E expectation, and recent Street research citing signs of dental market stabilisation alongside refreshed views following the Q4 report.

Analyst Commentary

Recent Street research around DENTSPLY SIRONA has focused on refreshed price targets, updated models after the Q4 report, and early signs that the dental market may be stabilizing. For you as an investor, the key themes come down to how much confidence analysts place in the company’s execution and what that implies for valuation risk and potential reward.

Bullish Takeaways

Bullish analysts have lifted price targets into a US$14 to US$18 range, which signals a view that the current valuation leaves room for upside if the company delivers on its updated plan.
Several models were refreshed following the Q4 report, suggesting that recent results and guidance provided enough visibility for analysts to refine revenue and margin assumptions rather than step back from the story.
Comments pointing to early evidence of dental market stabilisation support the idea that the external backdrop may be less of a drag, which could help the company focus more on execution than on offsetting end market weakness.
Inclusion on a list of preferred stock ideas for 2026 indicates that some research teams see DENTSPLY SIRONA as relatively attractive versus other mid cap names, based on their assessment of risk, growth potential, and valuation.

Bearish Takeaways

Not all analysts are outright positive, with several ratings framed as Neutral, In Line or Hold. This reflects ongoing caution around execution and limits how aggressive some are willing to be on valuation.
One prior cut to the price target at a major global bank highlights that sentiment has not been one way, and that earlier concerns around the earnings profile or risk factors still linger beneath the recent target increases.
The clustering of targets in the mid-teens suggests that, in some models, a meaningful part of the perceived upside is already captured. This leaves less room for error if revenue growth or margins fail to track to expectations.
References to model updates without an accompanying ratings upgrade imply that some analysts view the recent changes as fine tuning rather than a decisive shift in the growth or profitability outlook.

What’s in the News

Dentsply Sirona and Siemens Healthineers received FDA clearance in the U.S. for the MAGNETOM Free.Max Dental Edition, described as the first dental dedicated MRI system, following a clinical trial across multiple dental specialties that highlighted non ionizing imaging and specialized dental features. (Key Developments)
The company reported non cash goodwill and intangible asset impairment charges of $144 million, net of tax, in Q4 2025 related to the Orthodontic and Implant Solutions and Connected Technology Solutions segments, tied to lower equipment and implant volumes and lowered near term forecasts in the U.S. (Key Developments)
Dentsply Sirona issued earnings guidance for fiscal 2026, with expected net sales in a range of $3.5b to $3.6b. (Key Developments)
The company expanded its partnership with Burkhart Dental Supply. Burkhart will begin offering Dentsply Sirona’s full technology portfolio, including CEREC systems, Primescan scanners, and Axeos and Orthophos imaging systems, as part of a broader end to end offering for dental practices from April 1, 2026. (Key Developments)
Dentsply Sirona renewed its U.S. dental technology distribution agreement with Patterson Dental and announced an expanded technology collaboration with Benco Dental, keeping its digital systems such as CEREC and Primescan available across major distributor networks with showroom and service support. (Key Developments)

Valuation Changes

Fair Value: Modelled fair value has edged up from $14.43 to $14.54, reflecting a small adjustment in the updated assumptions.
Discount Rate: The discount rate has risen slightly from 9.76% to about 10.14%, which generally implies a higher required return for the risk being assumed.
Revenue Growth: Revenue growth input has moved from 40.26% to about 56.79%, indicating a higher growth assumption now incorporated into the model.
Net Profit Margin: Net profit margin has shifted marginally from 4.34% to about 4.32%, suggesting little change in the profitability assumption.
Future P/E: The future P/E multiple has nudged up from 23.74x to about 24.15x, signalling a slightly higher valuation multiple applied to future earnings in the refreshed analysis.

5 views

Key Takeaways

Expanded digital dentistry platforms and recurring revenue focus aim to raise margins, while streamlined operations target improved efficiency and cash flow.
Strategic investments in innovation and customer relationships are positioning the company to benefit from global dental industry growth and shifting care trends.
Persistent sales decline, cost inflation, competitive pressures, misaligned investments, and strategic execution risks collectively threaten long-term profitability and market share retention.

Catalysts

About DENTSPLY SIRONA

Develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.What are the underlying business or industry changes driving this perspective?

DENTSPLY SIRONA is leveraging the increasing global demand for advanced dental care-driven by an aging population and rising middle class in emerging markets-by ramping up investments in product innovation and tailored field support, which is expected to accelerate international revenue growth over the long term.
The company's continued expansion of digital dentistry platforms (such as DS Core) and emphasis on integrated software/hardware solutions aim to capture higher-margin recurring revenues as dental practices adopt digital workflows, supporting sustainable improvements in net margins and earnings.
Active cost reduction programs, operational streamlining, and supply chain optimization are in progress, with management indicating a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.
Management's focus on closer customer relationships, clinician workflow enhancements, and proceduralization is expected to drive sales force effectiveness and bolster share in aesthetic and restorative segments-areas benefiting from heightened health awareness and the global trend toward elective and preventive dental procedures.
Disciplined capital allocation toward innovation, organic growth, and financial flexibility, along with new leadership focused on execution, positions DENTSPLY SIRONA to capitalize on long-term industry consolidation and the shift toward value-based, high-quality dental care, which should support multi-year top-line and bottom-line growth.

DENTSPLY SIRONA Earnings and Revenue Growth

DENTSPLY SIRONA Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming DENTSPLY SIRONA's revenue will remain fairly flat over the next 3 years.
Analysts assume that profit margins will increase from -16.2% today to 4.3% in 3 years time.
Analysts expect earnings to reach $161.6 million (and earnings per share of $0.79) by about March 2029, up from -$598.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $234.7 million in earnings, and the most bearish expecting $101.5 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.2x on those 2029 earnings, up from -3.7x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.9x.
Analysts expect the number of shares outstanding to grow by 0.23% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.14%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent top-line challenges were evident, with global sales declining by nearly 5% year-over-year and continued U.S. sales weakness (down 11% ex-Byte), indicating DENTSPLY SIRONA is struggling to reignite sustainable revenue growth, especially in major geographies-an ongoing trend that could threaten long-term revenue and earnings outlook.
The company faces significant cost headwinds from tariffs, with the annualized impact escalating from $50 million to $80 million, only partially offset for 2025 and suggesting greater margin compression by 2026 if cost pass-through and mitigation measures falter-thus pressuring both gross and EBITDA margins over the long term.
Management repeatedly cited ongoing "softness" in high-margin elective categories (implants, CAD/CAM, imaging, U.S. orthodontics) and highlighted a double-digit decline in value implants, driven by both operational bottlenecks (e.g., Middle East disruptions) and increased competitive intensity; this reflects structural risks to both revenue growth and market share, especially as lower-cost competitors expand.
Recent impairment charges of $214 million related to goodwill and intangibles in the OIS and CTS segments underscore the misalignment of prior investment assumptions with current market realities, raising concerns about future returns on innovation investment, capital allocation discipline, and the risk of additional write-downs that could negatively affect reported earnings and investor confidence.
Management transitions and frequent references to needing more time for "listen-and-learn" sessions highlight strategic execution risk, especially amid an innovation-heavy and highly competitive landscape; ongoing integration and operational streamlining efforts may struggle to deliver expected efficiencies and could drive higher SG&A costs, hampering net margin expansion if not executed decisively and rapidly.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $14.54 for DENTSPLY SIRONA based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $18.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.7 billion, earnings will come to $161.6 million, and it would be trading on a PE ratio of 24.2x, assuming you use a discount rate of 10.1%.
Given the current share price of $10.95, the analyst price target of $14.54 is 24.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on DENTSPLY SIRONA?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Weigh Mixed Outlook for DENTSPLY SIRONA as Valuation and Guidance Adjusted